News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
360,204 Results
Type
Article (20784)
Company Profile (151)
Press Release (339269)
Section
Business (111897)
Career Advice (914)
Deals (19714)
Drug Delivery (96)
Drug Development (52887)
Employer Resources (83)
FDA (8525)
Job Trends (8235)
News (197030)
Policy (18392)
Tag
Academia (852)
Alliances (29841)
Alzheimer's disease (622)
Approvals (8500)
Artificial intelligence (94)
Bankruptcy (177)
Best Places to Work (5983)
Biosimilars (71)
Biotechnology (74)
Breast cancer (82)
Cancer (743)
Cardiovascular disease (69)
Career advice (745)
Cell therapy (120)
Clinical research (43734)
Collaboration (278)
Compensation (91)
COVID-19 (1145)
C-suite (68)
Data (825)
Diabetes (104)
Diagnostics (2157)
Drug pricing (97)
Earnings (40803)
Employer resources (77)
Events (51713)
Executive appointments (247)
FDA (8878)
Funding (200)
Gene therapy (101)
GLP-1 (509)
Government (1957)
Healthcare (6811)
Infectious disease (1203)
Inflammatory bowel disease (75)
Interviews (117)
IPO (7963)
Job creations (2498)
Job search strategy (679)
Layoffs (258)
Legal (4274)
Lung cancer (118)
Lymphoma (70)
Manufacturing (150)
Medical device (3254)
Medtech (3257)
Mergers & acquisitions (11838)
Metabolic disorders (358)
Neuroscience (818)
NextGen Class of 2024 (2645)
Non-profit (1098)
Northern California (816)
Obesity (229)
Opinion (179)
Patents (85)
People (34538)
Pharmaceutical (79)
Phase I (13637)
Phase II (18632)
Phase III (14825)
Pipeline (335)
Policy (73)
Postmarket research (1670)
Preclinical (4838)
Radiopharmaceuticals (170)
Rare diseases (160)
Real estate (3413)
Regulatory (12977)
Research institute (901)
Resumes & cover letters (145)
Southern California (738)
Startups (2089)
United States (7411)
Vaccines (241)
Weight loss (195)
Date
Today (80)
Last 7 days (308)
Last 30 days (1356)
Last 365 days (19119)
2024 (18855)
2023 (21236)
2022 (28976)
2021 (30545)
2020 (28439)
2019 (22534)
2018 (17417)
2017 (18795)
2016 (17721)
2015 (20550)
2014 (16013)
2013 (13617)
2012 (14586)
2011 (14897)
2010 (13673)
Location
Africa (444)
Asia (26525)
Australia (3945)
California (1836)
Canada (865)
China (192)
Colorado (75)
Connecticut (75)
Europe (56522)
Florida (262)
Illinois (184)
Indiana (135)
Maryland (265)
Massachusetts (1502)
Minnesota (111)
New Jersey (749)
New York (536)
North Carolina (404)
Northern California (816)
Ohio (67)
Pennsylvania (429)
South America (639)
Southern California (738)
Texas (237)
Washington State (167)
360,204 Results for "obi pharma usa".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
OBI Pharma Announces Phase 1/2 Study Initiation for OBI-992, a TROP2-Targeted Antibody-Drug Conjugate (ADC) for Cancer TherapyClinical trial to evaluate the safety and efficacy of OBI-992 in advanced solid tumors.
OBI Pharma, a clinical-stage oncology company, announced the initiation of a Phase 1/2 clinical trial of OBI-992, an antibody-drug conjugate targeting TROP2, an antigen overexpressed in multiple tumor types.
June 12, 2024
·
3 min read
OBI Pharma Announces Poster Presentations at the AACR 2024 Annual Meeting for OBI-992 and GlycOBI™ ADC platformPoster Presentations to highlight the latest research on OBI-992 (anti-TROP2 ADC) and OBI’s novel GlycOBI ADC platform
OBI Pharma, Inc. announced preclinical data for OBI-992, a potential best-in-class anti-TROP2 Antibody-Drug Conjugate.
March 18, 2024
·
6 min read
Drug Development
Biosion’s Partner OBI Pharma Announces FDA Clearance of IND Application for a Phase 1/2 Study of OBI-992 (TROP2 ADC)
The Partner of Biosion Inc., OBI Pharma, announced that the U.S. Food and Drug Administration has cleared an investigational new drug application for OBI-992, to conduct a Phase 1/2 study of its novel antibody drug conjugate cancer therapy targeting TROP2.
January 8, 2024
·
4 min read
Drug Development
OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase 1/2 Study of OBI-992
OBI Pharma, a clinical stage oncology company, announced that the U.S. Food and Drug Administration has cleared an investigational new drug application for OBI-992, to conduct a Phase 1/2 study of its novel antibody - drug conjugate cancer therapy targeting TROP2.
January 3, 2024
·
3 min read
Press Releases
TAE Life Sciences and Stella Pharma Announce Strategic Agreement for Development and Commercialization of BPA for BNCT Cancer Therapy in the USA and Europe
November 14, 2024
·
2 min read
Business
OBI Pharma Announces Executive Leadership Management Change – Heidi Wang, Ph.D. Appointed as Chief Executive Officer
Dr. Wang appointed by the OBI Pharma Board of Directors as Chief Executive Officer to lead OBI Pharma with a vision and to bring innovative cancer therapies to patients globally.
June 2, 2023
·
3 min read
Pharm Country
Natco Pharma Limited Completes Transition of DASH Pharmaceuticals into Natco Pharma USA, Furthering Strategic Presence in the United States
Natco Pharma Limited, a research and development -focused pharmaceutical company based in India, announced that DASH Pharmaceuticals, a company that markets, sells, and distributes generic pharmaceutical products, has officially transitioned to Natco Pharma USA, the U.S. subsidiary of Natco Pharma.
January 2, 2024
·
3 min read
OBI Pharma Announces Poster Presentations at AACR 2023 Annual Meeting for OBI-999 combination synergy with checkpoint inhibitor as well as Globo H-targeted CAR T-cell immunotherapy
OBI Pharma, Inc. announced preclinical data demonstrating significant synergistic effects of OBI-999 and pembrolizumab in four different cancer models, as well as the potent antitumor effect of a chimeric antigen receptor T-cell immunotherapy targeting Globo H.
April 10, 2023
·
3 min read
Pharm Country
Fosun Pharma USA Announces Its Attendance at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco
Fosun Pharma USA Inc. (“Fosun Pharma USA”) is pleased to announce that Chief Executive Officer, Rong Yang, and several Fosun Pharma USA executives, will be attending the 42nd Annual J.P. Morgan Healthcare Conference (JPM ’24), taking place in San Francisco, California, Jan. 8 - 11, 2024.
December 11, 2023
·
3 min read
Poolbeg Pharma PLC Announces Significant POLB 001 Patent Granted in USA
Poolbeg Pharma announces that, further to its announcement on20 March 2024,the Company has received the fully granted patent from the US Patent Office for its Immunomodulator II patent application.
May 1, 2024
·
5 min read
1 of 36,021
Next
